Here's a look at Tilray's recent performance compared with its largest competitors.
This startup has rapidly developed two potential blockbusters that are close to the finish line, and hardly anybody's noticed yet.
Here's what management wants investors to know about the future of the company's pharmaceutical segment.
The chairman of a giant U.S. cannabis company wants to use a controversial investing strategy.
Should you be as excited as the analysts who think these stocks are two-baggers in the making?
Lackluster results from Amgen's KRAS inhibitor program are clearing a path for Mirati's candidate.
Verily, Alphabet's life science venture, has switched gears to enter the wonkiest industry it could find.
According to the company, there's plenty of growth just a bit further ahead.
The transplant diagnostic service provider took some important steps forward in the first quarter.
The clinical-stage biotech hardly made a sound during the first three months of the year
It's been nearly seven years since the FDA refused to approve tafamidis' first new drug application, and the field is a lot more crowded now.
Can they make sparks fly again?
Canopy Growth investors won't like what Aphria's interim CEO has to say about the Acreage deal.
Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.
This is a great deal for at least one Curaleaf insider, but what about shareholders?
Investors are starting to wonder if there's anything that can lift this stock higher.
The first three months of the year weren't nearly as positive as investors had hoped for.
If you thought Monday was exciting, wait until you see what's on the slate for the rest of the week.
These A-list drugmakers must both contend with expiring patents, new drug uncertainties, and hungry competitors. But they're in different stages of their cyclical journeys.
It's been a rough few years, but an unexpected partnership could put the biotech's liver disease program back on top.